Skip to main content

Design Therapeutics, Inc. (DSGN)

Sector
Biotechnology
Last price
$9.84
As of

Kresmion compiles this page from DSGN's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

Design Therapeutics, Inc. (DSGN): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-04.

As of . Source: SEC EDGAR filings for DSGN. Method and limitations.

COMPANY DOSSIER

See the full DSGN dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for DSGN on one page. Preview it with sample data, then open it live with a free account.

Preview the DSGN dossier

Active events for DSGN

FREE, NO ACCOUNT

Every event on DSGN, as it fires

You are seeing 5 of 9 events recorded on DSGN since 2026-05-26.

The five above landed across 2 days. The other 4 were recorded on 2 other days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

DSGN positions held by the managers we follow (2026Q3)

What the managers we follow bought and sold in Q2 2026

Manager / securityMarket value% of reported value
RENAISSANCE TECHNOLOGIES LLC FundCUSIP 25056L103 · 2026Q3$3.8M0.01%

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, DSGN

More data on DSGN

DSGN against its peers

DSGN's return on equity of -32.8% ranks in the 83rd percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2025-12-31.

MetricDSGNPeer medianPercentilen
Revenue FY0.0 USD14.1M USD59
Operating marginn/a-449.9%n/a9
Net marginn/a-412.9%n/a9
Return on equity-32.8%-50.7%8320
1 year35.1%5.0%6920

Peers (21): BCAX, WVE, HELP, IMMX, KURA, ABUS, CGEM, CLYM, GERN, OLMA, FDMT, AVBP, ANNX, DBVT, ACHV, NVCT, SRZN, OBIO, FTH, XOMA.D, ENTX. Left out: ANL (period gap), APMD (no annual filing), ATTO (no annual filing), ETRA (no annual filing). Fiscal periods ending between 2025-03-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (DSGN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

Cite this data

Kresmion counts the managers it follows that reported a non-option position in DSGN on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on DSGN in the last 180 days.

Upstream: SEC EDGAR filings for DSGN

Kresmion, "Design Therapeutics, Inc. (DSGN) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/DSGN. Upstream data: SEC EDGAR filings for DSGN.

Link to this data (HTML):

<a href="https://kresmion.com/research/DSGN">Design Therapeutics, Inc. (DSGN) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow DSGN on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to DSGN for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the DSGN dossier
Share

The DSGN intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.